Illumina customers have been asked questions about the implications of the company’s $8 billion swoop for cancer-testing company Grail as part of the EU investigation of the deal, MLex has learned.
The questions indicate that the European Commission is concerned about Illumina’s ability and incentive to deny downstream companies access to